Home/ Stocks/ KYMR

Kymera Therapeutics, Inc. Common Stock

KYMR XNAS

$107.52 +1.11 (+1.04%) ▲ 15-min delayed

Open

$106.61

High

$108.12

Low

$104.78

Volume

463.6K

Market Cap

$8.85B

About Kymera Therapeutics, Inc. Common Stock

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 273 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$65.00M	$-61,211,000	$-0.62
FY 2025	$39.21M	$-311,351,000	$-3.69
Q3 2025	$2.76M	$-82,175,000	$-0.94
Q2 2025	$11.48M	$-76,614,000	$-0.95

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for KYMR yet. Check out our latest market news or earnings calendar.

Get KYMR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Kymera Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.